Detail akcie Eton Pharm Rg online

Business Summary: Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Eton Pharmaceuticals Inc revenues increased from $27.4M to $58.7M. Net loss increased 89% to $6.1M. Revenues reflect Product sales increase of 23% to $32.9M, Other Rev from Biz Related Activ increase from $500K to $3.3M. Higher net loss reflects Developing and commercializing prescription drug products segment loss increase of 3% to $3.3M.